MapLight Therapeutics Reports Third Quarter 2026 Results and Updates Progress on ML-007C-MA Clinical Programs
MapLight Therapeutics reported Q3 2026 results, with $463.4M in cash. It plans ZEPHYR-2 Phase 3 trial for ML-007C-MA in schizophrenia, with results expected in 2028. Phase 2 VISTA trial for Alzheimer’s disease psychosis is ongoing, with results expected in 2H 2027. The company raised $150M in August 2026 to support these trials.
How this was made

The 30-second read
Why it matters
Earnings release provides new guidance on cash runway and trial timelines, influencing valuation and risk assessment.
Market read
First‑time Q3 earnings data for MPLT, with cash position and trial milestones, relevant for biotech investors.
What to watch
Fast Track designation for ML‑007C‑MA could accelerate regulatory timeline.
Background
MapLight Therapeutics (Nasdaq:MPLT) is a clinical‑stage biopharma focused on CNS disorders, reporting its third‑quarter financials and trial updates.
Ticker impact
MapLight Therapeutics reported Q3 2026 results, cash position, and upcoming clinical milestones, providing fresh earnings data and guidance.
potential downside pressure as investors price in net loss and higher R&D spend
The company posted a $51.6M net loss and higher expenses, but disclosed $463M cash to fund trials through 2028.
Market effects
Highlights continued cash‑intensive development in CNS biotech, may affect peer valuations.
US‑listed biotech sector could see modest pullback.
Limited to investors tracking small‑cap biotech pipelines.
Counterpoint
Cash runway to 2028 may offset short‑term loss concerns, supporting a hold.
Key entities
- companyMapLight Therapeutics
Clinical‑stage biopharma developing ML‑007C‑MA and ML‑004.
